At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 106 enrolled
Drug / intervention
Proton Pump Inhibitors +1 moredrug
Likely dose
Proton Pump Inhibitors 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Controlled Study on the Effects of PPIs on Gastroesophageal Variceal Bleeding in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
In Brief
A Phase 4 clinical trial evaluating Proton Pump Inhibitors and Placebo for Liver Cirrhosis and Hypertension, Portal. Completed, enrolled 106 participants across 1 site.
Detailed Summary
This study is aimed at investigating the effect of PPIs on gastroesophageal varices in liver cirrhosis. Half of participants will receive PPI, while the other half will receive a placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cirrhosis, Hypertension, Portal
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
Enrollment StartMay 2017
First PostedJun 2017
Primary CompletionAug 2019
TodayJul 2026
First PostedJun 5, 2017
Enrollment StartMay 1, 2017
Primary CompletionAug 30, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.1 years ago
Interventions
Proton Pump Inhibitorsdrug
Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
Placebodrug
Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.